A. Masson-Lecomte
- Urology top 1%
- Urological Disorders and Treatments 26
- Surgery top 2%
- Bladder and Urothelial Cancer Treatments 70
- Urinary and Genital Oncology Studies 53
-
- Renal cell carcinoma treatment 10
- Prostate Cancer Diagnosis and Treatment 9
- Prostate Cancer Treatment and Research 6
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 10
-
- Renal and related cancers 5
A. Masson-Lecomte
77 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Urology 453
- Surgery 1.7k
- Pulmonary and Respiratory Medicine 665
- Oncology 462
- Cancer Research 154
Countries citing papers authored by A. Masson-Lecomte
This map shows the geographic impact of A. Masson-Lecomte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Masson-Lecomte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Masson-Lecomte more than expected).
Fields of papers citing papers by A. Masson-Lecomte
This network shows the impact of papers produced by A. Masson-Lecomte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Masson-Lecomte. The network helps show where A. Masson-Lecomte may publish in the future.
Co-authorship network
The 25 scholars most cited alongside A. Masson-Lecomte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Updatebreakdown → | 2024 | 54 |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 10 | |
| 8 | European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Updatebreakdown → | 2023 | 239 |
| 9 | 2023 | 1 | |
| 10 | 2023 | 5 | |
| 11 | 2023 | 3 | |
| 12 | 2023 | 5 | |
| 13 | 2022 | 11 | |
| 14 | 2022 | 7 | |
| 15 | 2022 | 2 | |
| 16 | 2022 | 1 | |
| 17 | 2020 | 16 | |
| 18 | 2018 | 5 | |
| 19 | 2018 | 23 | |
| 20 | 2016 | 4 |
About A. Masson-Lecomte
A. Masson-Lecomte is a scholar working on Urology, Surgery, Oncology, Pulmonary and Respiratory Medicine and Rheumatology, having authored 87 papers that have together received 2.2k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (70 papers), Urinary and Genital Oncology Studies (53 papers), Urological Disorders and Treatments (26 papers), Renal cell carcinoma treatment (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers), Prostate Cancer Treatment and Research (6 papers) and Renal and related cancers (5 papers). The work is most often cited by research in Urology (453 citations), Surgery (1.7k citations), Pulmonary and Respiratory Medicine (665 citations), Oncology (462 citations) and Cancer Research (154 citations). A. Masson-Lecomte has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Morgan Rouprêt, Éva Compérat, Shahrokh F. Shariat, Thomas Seisen, Bas W.G. van Rhijn, Otakar Čapoun, Paolo Gontero, Fredrik Liedberg, Hugh Mostafid and Viktor Soukup. Their work appears in journals such as World Journal of Urology, British Journal of Urology, European Urology, European Urology Oncology and Urologic Oncology Seminars and Original Investigations.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.